Congenital Diaphragmatic Hernia Drugs Global Market Report 2024

The global congenital diaphragmatic hernia drugs market has grown strongly in recent years. It will grow from $4.04 billion in 2023 to $4.38 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to high incidence of congenital diaphragmatic hernia cases, increasing awareness of congenital diaphragmatic hernia, government initiatives.

The global congenital diaphragmatic hernia drugs market is expected to see strong growth in the next few years. It will grow to $5.84 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to growing healthcare expenditure, rare disease incentives, growing patient advocacy groups, regenerative medicine, targeted therapies. Major trends in the forecast period include advancements in medical research, advancements in drug development, advances in fetal surgery, pharmacological lung growth, increasing use of personalized medicine, development of new and innovative drug delivery systems, digital health technologies.

The increasing rate of birth defects is expected to act as a catalyst for the expansion of the congenital diaphragmatic hernia drug market. Birth defects encompass structural or functional anomalies present at birth that can significantly impact a baby's overall health and development. Treatment for congenital diaphragmatic hernia involves a comprehensive approach that includes prenatal screening, genetic counseling, and targeted therapies. These measures are designed to reduce the occurrence of birth defects associated with congenital diaphragmatic hernia and enhance the potential for early intervention and personalized care, ultimately improving the overall well-being and quality of life for affected individuals. For example, in March 2023, the World Health Organization (WHO), an intergovernmental organization based in the US, reported that approximately 8 million infants are born with birth defects each year, with low- and middle-income countries accounting for nine out of every ten significant cases. Moreover, an estimated 240,000 newborns worldwide succumb to congenital disorders within 28 days of birth annually. Consequently, the increasing prevalence of birth defects serves as a driving force behind the congenital diaphragmatic hernia drug market's growth.

The increasing occurrence of congenital diaphragmatic hernia (CDH) is poised to be a significant driver for the growth of the congenital diaphragmatic hernia drug market. CDH is a congenital birth defect characterized by an abnormal opening or hole in the diaphragm, the muscle that separates the chest cavity from the abdominal cavity. These drugs have the potential to yield improved outcomes for CDH patients, including enhanced lung function and a reduction in pulmonary hypertension. For instance, as of October 2022, data from the Cleveland Clinic, a non-profit academic medical center based in the United States, indicates that CDH occurs in approximately 1 in 2,500 to 3,500 live births. Reports further suggest that a notable proportion of infants diagnosed with CDH, ranging from 70% to 90%, achieve survival. Consequently, the increasing incidence of congenital diaphragmatic hernia (CDH) serves as a driving force behind the expansion of the congenital diaphragmatic hernia drug market.

The presence of limited treatment options can potentially restrict access to care and act as a constraining factor in the growth of the congenital diaphragmatic hernia (CDH) market during the forecast period. Both patients and healthcare providers encounter challenges in managing CDH due to the scarcity of viable alternative therapies, which contributes to a stagnant market landscape with a dearth of innovative solutions. For instance, as of August 2021, data from the World Health Organization, an international agency headquartered in Switzerland, revealed that an estimated 15 million children were born prematurely annually. This figure accounted for more than one in every ten newborns. Alarmingly, in low-income settings, approximately half of the infants born at or before 32 weeks (equivalent to 2 months premature) lose their lives due to the absence of practical and cost-effective care measures, including warmth, breastfeeding support, and basic treatments for infections and respiratory conditions. Hence, the lack of effective treatment options represents a significant impediment to the growth of the congenital diaphragmatic hernia (CDH) market.

The leading companies in the congenital diaphragmatic hernia (CDH) market are at the forefront of introducing cutting-edge treatment innovations through the application of coating technology to maintain their market presence. This novel approach involves the utilization of coating technology for synthetic hernia mesh embedded with drugs, enhancing the treatment landscape. The coating technology entails the application of a specialized layer onto the surface of synthetic mesh used in hernia repair procedures. For example, in April 2022, Ariste Medical, a pre-commercial drug and device company based in the United States, received clearance from the U.S. Food and Drug Administration (FDA) to market its drug-embedded synthetic hernia mesh. This innovative mesh is designed to mitigate the risk of microbial colonization during surgical implantation by combining the advantages of polypropylene mesh with a biocompatible coating that supports antibiotic residency. This versatile coating technology holds promise for both implantable and non-implantable medical devices and exhibits potential applications in materials like polyurethane and ePTFE. Furthermore, Ariste Medical's coating technology has the potential to revolutionize ePTFE surgical implants, including those used in hernia repair surgeries.

In July 2021, Becton, Dickinson and Company, a prominent medical technology firm based in the United States, completed the acquisition of Tepha Inc. for an undisclosed sum. This strategic move is aimed at reinforcing Becton, Dickinson and Company's growth potential and capacity for innovation in the realm of surgical mesh and soft tissue repair, reconstruction, and regeneration. Tepha Inc., also based in the United States, specializes in medical device manufacturing with a focus on tissue engineering and regenerative medicine. Their product range includes surgical sutures, films, and composite meshes, which are crucial components in procedures such as congenital diaphragmatic hernia surgery.

Major players in the congenital diaphragmatic hernia drugs market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline Plc, Medtronic plc, Amgen Inc., Becton, Dickinson and Company, Viatris Inc., B. Braun SE, Sun Pharmaceutical Industries Ltd., C.R. Bard Inc., W. L. Gore & Associates, Chiesi Farmaceutici S.p.A., Getinge AB, Ferring Pharmaceuticals, Mallinckrodt Pharmaceuticals, Integra LifeSciences Corporation, Genentech Inc., LifeCell International Private Limited, Cook Biotech Inc., Cousin Biotech SAS, Dipro Medical Devices S.R.L., Aspide Medical.

North America was the largest region in the congenital diaphragmatic hernia drugs market in 2023. The regions covered in congenital diaphragmatic hernia drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the congenital diaphragmatic hernia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of drugs for congenital diaphragmatic hernia include posterolateral Bochdalek hernia, anterior Morgagni hernia, and hiatal hernia. Posterolateral Bochdalek hernia, for example, is a specific form of congenital diaphragmatic hernia where a defect in the rear part of the diaphragm allows abdominal organs to enter the chest cavity. Treatment options vary, including extracorporeal membrane oxygenation (ECMO), and they can be administered during both prenatal and postnatal phases. These medications and treatments cater to a range of end-users, including hospitals, homecare settings, specialty clinics, and others.

This report provides congenital diaphragmatic hernia drugs market statistics, including congenital diaphragmatic hernia drugs industry global market size, regional shares, competitors with a congenital diaphragmatic hernia drugs market share, detailed congenital diaphragmatic hernia drugs market segments, market trends and opportunities and any further data you may need to thrive in the congenital diaphragmatic hernia drugs industry. This congenital diaphragmatic hernia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The congenital diaphragmatic hernia drugs market consists of revenues earned by entities by providing surgical treatments and medical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The congenital diaphragmatic hernia drug market also includes sales of pain management medications, antibiotics, vasoactive agents, dobutamine and milrinone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.